Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1957 1
1958 2
1964 1
1965 1
1966 1
1973 2
1974 2
1976 1
1979 2
1980 2
1981 4
1983 1
1984 1
1987 3
1988 1
1989 2
1991 1
1992 4
1993 1
1994 6
1995 4
1996 10
1997 5
1999 1
2000 3
2001 2
2002 7
2003 2
2004 3
2005 2
2006 5
2007 5
2008 7
2009 9
2010 4
2011 7
2012 4
2013 6
2014 2
2015 4
2016 2
2018 1
2019 4
2020 4
2021 5
2022 5
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Al-Batran SE, et al. Among authors: bernhard h. Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11. Lancet. 2019. PMID: 30982686 Clinical Trial.
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL). Rummel MJ, et al. Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20. Lancet. 2013. PMID: 23433739 Clinical Trial.
In reply.
Bernhard HF, Holz FG. Bernhard HF, et al. Dtsch Arztebl Int. 2014 May 16;111(20):366. doi: 10.3238/arztebl.2014.0366b. Dtsch Arztebl Int. 2014. PMID: 24882633 Free PMC article. No abstract available.
Super-additive cooperation.
Efferson C, Bernhard H, Fischbacher U, Fehr E. Efferson C, et al. Among authors: bernhard h. Nature. 2024 Feb;626(8001):1034-1041. doi: 10.1038/s41586-024-07077-w. Epub 2024 Feb 21. Nature. 2024. PMID: 38383778 Free PMC article.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Goldschmidt H, et al. Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0. Lancet Haematol. 2022. PMID: 36328040 Clinical Trial.
Immunity to oncogenic proteins.
Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Qin HL, Takahashi M, Chen W. Cheever MA, et al. Among authors: bernhard h. Immunol Rev. 1995 Jun;145:33-59. doi: 10.1111/j.1600-065x.1995.tb00076.x. Immunol Rev. 1995. PMID: 7590829 Review. No abstract available.
Use of tumour-responsive T cells as cancer treatment.
Disis ML, Bernhard H, Jaffee EM. Disis ML, et al. Among authors: bernhard h. Lancet. 2009 Feb 21;373(9664):673-83. doi: 10.1016/S0140-6736(09)60404-9. Lancet. 2009. PMID: 19231634 Free PMC article. Review.
Vaccination against the HER-2/neu oncogenic protein.
Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML. Bernhard H, et al. Endocr Relat Cancer. 2002 Mar;9(1):33-44. doi: 10.1677/erc.0.0090033. Endocr Relat Cancer. 2002. PMID: 11914181 Review.
Best practices for perinatal palliative care.
Ryan A, Bernhard H, Fahlberg B. Ryan A, et al. Among authors: bernhard h. Nursing. 2015 Oct;45(10):14-5. doi: 10.1097/01.NURSE.0000471422.49754.9b. Nursing. 2015. PMID: 26372234 No abstract available.
147 results